

Fig. 1




Fig. 2




Fig. 3





FIG. 4



Non-validated output
Symbols represent censored observations
Active arms include 25 mg QD, 25 mg BID, 50 mg BID, 100 mg BID

Fig. 5





Fig. 6



*No BARC Type 5 bleeding was observed.




Fig. 8A




Fig. 8B






Fig. 8C



Treatment 1: 25 mg mifexolan (1x 25 mg film-coated tablet) BID for 5 days (administered in the morning after at least 10-hour overnight fasting and in the evening 12 hours after the morning dose)

Treatment 2: 25 mg mifexolan (1x 25 mg Phase 2 oral capsule) BID for 5 days (administered in the morning after at least 10-hour overnight fasting and in the evening 12 hours after the morning dose)

Fig. 8D



Treatment 1: 25 mg milvexian (1 x 25 mg film-coated TC oral tablet) BID for 5 days (administered in the morning after at least 10-hour overnight fasting and in the evening 12 hours after the opening dose)
Treatment 2: 25 mg milvexian (1 x 25 mg Phase 2 oral capsule) BID for 5 days (administered in the morning after at least 10-hour overnight fasting and in the evening 12 hours after the morning dose)

Fig. 9

